KLUS Pharma has been committed to the discovery and expansion of novel therapeutics for various diseases since it was founded in 2014. We focus on developing novel biologics, including monoclonal antibodies, multi-specific antibodies, and antibody-drug conjugates (ADC) for the treatment of cancer as well as cardiovascular disease and other severe diseases.

Our platforms for antibody discovery, including hybridoma technology and phage display, create promising ways to expedite the movement of high-quality biologic drugs from bench to market. We work closely with professionals in the fields of immuno-oncology, autoimmunity, respiratory, and cardiovascular diseases to identify and assess multiple drug targets. Currently, over 10 therapeutic antibodies are in preclinical/clinical development.

Our Mission

At KLUS, our mission is to bring better health and a better life to our patients and their family. We pursue and provide safer biologic therapeutics to create a better world.

Our Team

The KLUS team is comprised of three departments: R&D, Clinical Trial, and Business Development. All three groups operate independently, but collaborate to achieve our common mission.

  • R&D

    The Antibody Discovery and Development team has extensive experience in developing mAbs for a wide range of therapeutic targets. The team has established six R&D technical platforms, including hybridoma, phage display, protein engineering, developability assessment, bioanalytics, and cell line development. Each platform is led by an exceptional expert with years of experience in academia and/or industry.

  • Clinical team

    The Clinical team has deep knowledge and experience with clinical studies, conducting clinical trials and regularly filing for approvals in the US and/or EU. Each team member has more than 10 years of clinical development experience in academic institutions and/or the pharmaceutical industry. We attract some of the leading physician-scientists in the US to join our Scientific Advisory Board and provide support for our clinical projects.

  • Business Development

    A good business development team is hard to come by, but the BD team at KLUS is driven by the challenge to grow. Always on top of prospects and close deals that allow us to prosper, they have the track record and necessary skills to bring in more business.

  • May 2018——Phase I clinical trial initiated for A166
  • March 2018——IND filed for ADC drug A166
  • September 2016——Novel projects R&D started
  • October 2014——KLUS Pharma founded
  • Add: 8 Clarke Drive, Suite 4, Cranbury, New Jersey 08512
  • Email: Admin@kluspharma.com
  • Phone: (+ 001) 609-662-1913
  • Fax: (+ 001) 609-662-1918